1. Home
  2. IFRX vs JFB Comparison

IFRX vs JFB Comparison

Compare IFRX & JFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • JFB
  • Stock Information
  • Founded
  • IFRX 2007
  • JFB 2014
  • Country
  • IFRX Germany
  • JFB United States
  • Employees
  • IFRX N/A
  • JFB N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • JFB
  • Sector
  • IFRX Health Care
  • JFB
  • Exchange
  • IFRX Nasdaq
  • JFB NYSE
  • Market Cap
  • IFRX 53.5M
  • JFB 64.2M
  • IPO Year
  • IFRX 2017
  • JFB 2025
  • Fundamental
  • Price
  • IFRX $0.85
  • JFB $8.01
  • Analyst Decision
  • IFRX Strong Buy
  • JFB
  • Analyst Count
  • IFRX 4
  • JFB 0
  • Target Price
  • IFRX $7.75
  • JFB N/A
  • AVG Volume (30 Days)
  • IFRX 371.5K
  • JFB 44.3K
  • Earning Date
  • IFRX 08-07-2025
  • JFB 08-11-2025
  • Dividend Yield
  • IFRX N/A
  • JFB N/A
  • EPS Growth
  • IFRX N/A
  • JFB N/A
  • EPS
  • IFRX N/A
  • JFB 0.00
  • Revenue
  • IFRX $140,242.00
  • JFB $25,946,544.00
  • Revenue This Year
  • IFRX N/A
  • JFB N/A
  • Revenue Next Year
  • IFRX $6,309.47
  • JFB N/A
  • P/E Ratio
  • IFRX N/A
  • JFB $1,995.92
  • Revenue Growth
  • IFRX 30.90
  • JFB N/A
  • 52 Week Low
  • IFRX $0.71
  • JFB $3.39
  • 52 Week High
  • IFRX $2.82
  • JFB $10.46
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 45.30
  • JFB N/A
  • Support Level
  • IFRX $0.78
  • JFB N/A
  • Resistance Level
  • IFRX $0.93
  • JFB N/A
  • Average True Range (ATR)
  • IFRX 0.05
  • JFB 0.00
  • MACD
  • IFRX 0.03
  • JFB 0.00
  • Stochastic Oscillator
  • IFRX 42.32
  • JFB 0.00

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About JFB JFB CONSTRUCTION HOLDINGS

JFB Construction Holdings is a commercial and residential real estate construction and development company. It is engaged in retail corporate buildouts, multifamily community developments and luxury residential homes, with a focus on fostering long-term relationships with clients, partners, and communities. The company operates in three distinct business segments: Commercial Construction, Residential Construction, and Real Estate Development. Key revenue is generated from Commercial Construction: This segment includes all activities related to the construction of commercial properties such as office buildings, retail spaces, and industrial facilities.

Share on Social Networks: